
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" article-type="research-article" xml:lang="en"><processing-meta tagset-family="jats" base-tagset="archiving" mathml-version="3.0" table-model="xhtml"><custom-meta-group><custom-meta assigning-authority="highwire" xlink:type="simple"><meta-name>recast-jats-build</meta-name><meta-value>d8e1462159</meta-value></custom-meta></custom-meta-group></processing-meta><front><journal-meta><journal-id journal-id-type="hwp">jitc</journal-id><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="publisher-id">40425</journal-id><journal-title-group><journal-title>Journal for ImmunoTherapy of Cancer</journal-title><abbrev-journal-title abbrev-type="publisher">J Immunother Cancer</abbrev-journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BMJ Publishing Group Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s40425-019-0688-8</article-id><article-id pub-id-type="manuscript">688</article-id><article-id pub-id-type="doi">10.1186/s40425-019-0688-8</article-id><article-id pub-id-type="pmid">31395097</article-id><article-id pub-id-type="apath" assigning-authority="highwire">/jitc/7/1/211.atom</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Correction to: IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Choi</surname><given-names>Yeon Ho</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lim</surname><given-names>Eun Jin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kim</surname><given-names>Se Wha</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Moon</surname><given-names>Yong Wha</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Park</surname><given-names>Kyung Soon</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes" xlink:type="simple"><name name-style="western"><surname>An</surname><given-names>Hee-Jung</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="corresp" rid="cor6">f</xref></contrib><aff id="Aff1">
<label>Aff1</label>
<institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0647 3511</institution-id><institution-id institution-id-type="GRID">grid.410886.3</institution-id><institution content-type="org-division" xlink:type="simple">Institute for Clinical Research, CHA Bundang Medical Center</institution><institution content-type="org-name" xlink:type="simple">CHA University</institution></institution-wrap>
<addr-line content-type="city">Sungnam</addr-line>
<addr-line content-type="state">Gyeonggi-do</addr-line>
<country country="KR">Republic of Korea</country>
</aff><aff id="Aff2">
<label>Aff2</label>
<institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0647 3511</institution-id><institution-id institution-id-type="GRID">grid.410886.3</institution-id><institution content-type="org-division" xlink:type="simple">Department of Pathology, CHA Bundang Medical Center</institution><institution content-type="org-name" xlink:type="simple">CHA University</institution></institution-wrap>
<addr-line content-type="city">Sungnam</addr-line>
<addr-line content-type="state">Gyeonggi-do</addr-line>
<country country="KR">Republic of Korea</country>
</aff><aff id="Aff3">
<label>Aff3</label>
<institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0647 3511</institution-id><institution-id institution-id-type="GRID">grid.410886.3</institution-id><institution content-type="org-division" xlink:type="simple">Department of Medical Oncology, CHA Bundang Medical Center</institution><institution content-type="org-name" xlink:type="simple">CHA University</institution></institution-wrap>
<addr-line content-type="city">Sungnam</addr-line>
<addr-line content-type="state">Gyeonggi-do</addr-line>
<country country="KR">Republic of Korea</country>
</aff><aff id="Aff4">
<label>Aff4</label>
<institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0647 3511</institution-id><institution-id institution-id-type="GRID">grid.410886.3</institution-id><institution content-type="org-division" xlink:type="simple">Department of Biomedical Science</institution><institution content-type="org-name" xlink:type="simple">CHA University</institution></institution-wrap>
<addr-line content-type="city">Sungnam</addr-line>
<addr-line content-type="state">Gyeonggi-do</addr-line>
<country country="KR">Republic of Korea</country>
</aff></contrib-group><author-notes><corresp id="cor6">
<label>f</label>
<email xlink:type="simple">hjahn@cha.ac.kr</email>
</corresp></author-notes><pub-date date-type="pub" iso-8601-date="2019-12" pub-type="ppub" publication-format="print"><month>12</month><year>2019</year></pub-date><pub-date date-type="pub" iso-8601-date="2019-08-08" pub-type="epub-original" publication-format="electronic"><day>8</day><month>8</month><year>2019</year></pub-date><pub-date iso-8601-date="2019-11-18T10:22:57-08:00" pub-type="hwp-received"><day>18</day><month>11</month><year>2019</year></pub-date><pub-date iso-8601-date="2019-11-18T10:22:57-08:00" pub-type="hwp-created"><day>18</day><month>11</month><year>2019</year></pub-date><pub-date iso-8601-date="2019-08-08T00:00:00-07:00" pub-type="epub"><day>8</day><month>8</month><year>2019</year></pub-date><volume>7</volume><issue>1</issue><elocation-id>211</elocation-id><permissions><copyright-statement>© The Author(s).</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/" xlink:type="simple"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/" xlink:type="simple">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="40425_2019_Article_688_nlm.pdf" xlink:type="simple"/><related-article related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1186/s40425-019-0652-7" xlink:type="simple"/><abstract id="Abs1" xml:lang="en"><p>.</p></abstract><custom-meta-group><custom-meta xlink:type="simple"><meta-name>publisher-imprint-name</meta-name><meta-value>BioMed Central</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>volume-issue-count</meta-name><meta-value>1</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>issue-article-count</meta-name><meta-value>0</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>issue-pricelist-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>issue-copyright-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>article-contains-esm</meta-name><meta-value>No</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>article-registration-date-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>article-registration-date-month</meta-name><meta-value>7</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>article-registration-date-day</meta-name><meta-value>23</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>journal-product</meta-name><meta-value>ArchiveJournal</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/40425_2019_Article_688.pdf</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>pdf-type</meta-name><meta-value>Typeset</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>article-type</meta-name><meta-value>Erratum</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>journal-subject-primary</meta-name><meta-value>Medicine &amp; Public Health</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>journal-subject-secondary</meta-name><meta-value>Oncology</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>journal-subject-secondary</meta-name><meta-value>Immunology</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>journal-subject-collection</meta-name><meta-value>Medicine</meta-value></custom-meta><custom-meta xlink:type="simple"><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="CrossLinking"><p>The original article can be found online at 10.1186/s40425-019-0652-7</p></notes></front><body><p id="Par2">
<bold>Correction to: J Immuno Ther Cancer (2019) 7:168</bold>
</p><p id="Par3">
<bold>https://doi.org/10.1186/s40425-019-0652-7</bold>
</p><p id="Par4">After publication of the original article [<xref ref-type="bibr" rid="CR1">1</xref>], the authors reported that three figures published in their manuscript are wrong.</p><p id="Par5">The correct version of the figures can be found below:</p><p id="Par6">Figs. <xref rid="Fig1" ref-type="fig">1</xref>, <xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">4</xref>
<fig id="Fig1" position="float" orientation="portrait"><object-id pub-id-type="publisher-id">Fig1</object-id><label>Fig. 1</label><caption xml:lang="en"><p>Cytokine regulation of the proliferation and cytotoxicity of primary NK cells<italic toggle="yes">.</italic>
<bold>a</bold> CD3-CD56+ NK cells (0.6–1.8 × 10<sup>6</sup> / well) isolated from PBMCs were cultured in the indicated cytokines for 21 days. Primary NK cells were imaged using an inverted microscope and counted. Representative images of aggregates of growing primary NK cells in different culture conditions. Bars represent 500 μm; original magnification × 40. <bold>b</bold> The graph represents the total NK cell number of each group. Symbols indicate cytokine treatment groups (<italic toggle="yes">n</italic> = 3 / group): IL-2 (▲), IL-15 (▼), IL-15/18 (◆), IL-15/27 (○), IL-18/27 (□), and IL-15/18/27 (<italic toggle="yes">red</italic>). <bold>c</bold>. Fold expansion of NK cell numbers compared with those on day 0 following culture of CD3-CD56+ NK cells with the indicated cytokines. The graphs show the mean ± SD. * <italic toggle="yes">P</italic> &lt; 0.05, ** <italic toggle="yes">P</italic> &lt; 0.01, and *** <italic toggle="yes">P</italic> &lt; 0.001, compared with day 0. <bold>d</bold> NK cell viability. The viable cell numbers were determined by trypan blue staining on days 7, 14 and 21. * <italic toggle="yes">P</italic> &lt; 0.05, compared with day 14. <bold>e</bold> NK cytotoxicity assays of various cytokine-stimulated NK cells with K562 target cells on days 7, 14 and 21. The E:T ratios ranged from 0:1 to 10:1. After 4 h of incubation at 37 °C, the lysis of target cells was measured by ELISA. E:T indicates the effector-to-target ratio. The cytolytic activity of human NK cells stimulated with IL-15/18/27 toward K562 cells was significantly increased (*<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.01, *** <italic toggle="yes">P</italic> &lt; 0.001) compared with that of resting NK cells (day 0) at the same E:T ratio. <bold>f</bold> Supernatants were analyzed for IFN-ɣ secretion by ELISA. The data presented are the mean ± SD of three separate experiments., *** <italic toggle="yes">P</italic> &lt; 0.001, compared with IL-2 treated group</p></caption><graphic specific-use="JPEG" mime-subtype="PNG" xlink:href="40425_2019_688_Fig1_HTML.jpg" position="float" orientation="portrait" xlink:type="simple"/></fig>
<fig id="Fig2" position="float" orientation="portrait"><object-id pub-id-type="publisher-id">Fig2</object-id><label>Fig. 2</label><caption xml:lang="en"><p>Flow cytometry analysis of NK cell receptors on human primary NK cells. (A) Cell surface expression of the indicated molecules on primary human NK cells on day 0 and day 21. Cells were stimulated with cytokine combinations (IL-15, IL-18, and IL-27) for 21 days. Primary NK cells from healthy donors were stained for expression of NK cell activating receptors (<bold>a</bold>) and inhibitory receptors (<bold>b</bold>), as indicated. Histograms show representative examples of NK cell receptor expression (shadow area) and show the percentage of NK cells positive for a given receptor relative to the isotype control (gray lines). NK cells were gated as viable, single, CD3-CD56+ cells. (<bold>c</bold>-<bold>d</bold>) Statistical analysis for the difference in NK cell receptor expression between day 0 and day 21. Significant differences are indicated in the graph as follows: *<italic toggle="yes">P</italic> &lt; 0.05 and ** <italic toggle="yes">P</italic> &lt; 0.01, compared with day 0. n.s: not significant</p></caption><graphic specific-use="JPEG" mime-subtype="PNG" xlink:href="40425_2019_688_Fig2_HTML.jpg" position="float" orientation="portrait" xlink:type="simple"/></fig>
<fig id="Fig3" position="float" orientation="portrait"><object-id pub-id-type="publisher-id">Fig3</object-id><label>Fig. 4</label><caption xml:lang="en"><p>Measurement of NK cell cytotoxicity by imaging cytometry. <bold>a</bold> K562 target cells were stained with calcein AM. After 4 h of incubation with 21-day-expanded NK cells (stimulated with IL-15/18/27), fluorescence images show progressive loss of fluorescence intensity of the K562 cells at various E:T ratios. Representative bright field, calcein, and overlay images showing E:T ratio-dependent target cell killing. Original magnification × 100. The graph represents the percentage of viable or dead target cells. *** <italic toggle="yes">P</italic> &lt; 0.001 was considered signigicant. <bold>b</bold> A high power view of the calcein AM assay showing the progress of NK cell killing. Nearly all of the target cells were killed in a 10:1 effector-to-target cell sample, while calcein AM-labeled K562 cells were not killed in the control image. Bright-field and fluorescence overlay images of calcein show K562 cells undergoing apoptotic death following interaction with NK cells. The images were derived from a Zeiss LSM 510 microscope (<italic toggle="yes">left</italic>). The graph (<italic toggle="yes">right</italic>) represents cytotoxicity against K562 cells with expanded NK cells on days 7, 14 and 21 over the 4 h of the assay. *<italic toggle="yes">P</italic> &lt; 0.05, ** <italic toggle="yes">P</italic> &lt; 0.01, ***<italic toggle="yes">P</italic> &lt; 0.001 compared with day 0. Symbols indicate cytokine treatment groups (<italic toggle="yes">n</italic> = 3 / group): day 0 (▲), day 7 (▼), day 14 (◆), day 21 (red ○), and K562 cells only (●). <bold>c</bold> Immunoblot analysis for caspase-8, − 9 and − 3 activation. K562 cells were cocultured with primary NK cells for 4 h. Immunoblotting was performed with antibodies specific for caspase-8, − 9 and − 3 and their cleaved forms. β-actin was used as an internal standard. <bold>d</bold> Protein bands were quantitated by densitometric analysis. The ratio of the intensity of protein bands relative to that of β-actin was calculated. Bar graph represents the relative expression of cleaved caspase-8, − 9 and − 3 proteins. Experiments were repeated three times with similar results</p></caption><graphic specific-use="JPEG" mime-subtype="PNG" xlink:href="40425_2019_688_Fig3_HTML.jpg" position="float" orientation="portrait" xlink:type="simple"/></fig>
</p><p id="Par7">The original article has been corrected.</p><p id="Par8">The publisher apologies for the inconvenience.</p></body><back><ref-list id="Bib1"><title>Reference</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Choi</surname>
<given-names>YH</given-names>
</string-name>, <etal>et al</etal>
</person-group>. <article-title xml:lang="en">IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells</article-title>. <source>J ImmunoTherapy Cancer</source>. <year>2019</year>;<volume>7</volume>:<fpage>168</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s40425-019-0652-7" xlink:type="simple">doi:10.1186/s40425-019-0652-7</ext-link>
</mixed-citation></ref></ref-list></back></article>